31 P spectra (ppm) were measured on a Bruker 200 MHz apparatus unless stated otherwise.
N-4,
4,4-Dimethoxytrityl chloride (745mg; 2.2 mmol) was added to a solution of gemcitabine (680 mg, 2 mmol) in dry pyridine (20 mL). The reaction mixture was stirred at 0ÛC for 3 hours and then allowed to stand 1h at room temperature. Pyridine was then removed under reduced pressure and the residue was dissolved in CHCl 3 (10 mL) and washed with H 2 O (3x 10 mL), dried over anhydrous MgSO 4 and concentrated in vacuo. The product was isolated by silica gel column chromatography using methanol in chloroform (0 8%) as an eluent. 5'-ODimethoxytrityl-2',2'-difluoro-2'-deoxycytidine was obtained in 64% yield. FAB-MS m/z: (M-1) 564; 1 H NMR (CDCl 3 ): 7. 74-7.70 (d, 2H), 7.43-7.28 (m, 9H), 6.85-6.80 (d, 4H), 6.47-6.39 (t, 1H), 5.52-5.48 (d, 1H), 4.46-4.12 (m, 1H), 4.07-4.03 (d, 1H), 3.77 (s, 6H), 3.58-3.39 (m, 2H) . Then 5'-O-dimethoxytrityl-2',2'-difluoro-2'-deoxycytidine (720mg, 1.3 mmol) was dissolved in dry pyridine and into this solution benzoyl chloride (350μl; 3.04mmol) was added at 0ÛC. The reaction mixture was stirred for 2h at room temperature and then concentrated under reduced pressure to 1/3 volume. The residue was dissolved in benzene (10 mL), the precipitated pyridine hydrochloride was filtered off and then water (2 mL) was added. After 15min the residue was concentrated in vacuo. The residue was dissolved in anhydrous CH 2 Cl 2 (40 mL) and into this solution p-toluenesulfonic acid monohydrate (360 mg; 1.9 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours and then was concentrated in vacuo. The crude product 2 was purified by column chromatography on silica gel (0 2% methanol in chloroform as an eluent) in 91% yield. 1 -2-thio-1,3,2-oxathiaphospholane (9) . To a mixture of 3-hydroxypropionitrile (5) (30mg, 29μL, 0.42 mmol), elemental sulfur (128mg, 0.5mmol) and pyridine (2mL) 2-chloro-1,3,2-oxathiaphospholane 1 (6) (57mg, 0.4mmol) was added dropwise. The reaction mixture was stirred at room temperature for 12 h. Then the solvent was removed in vacuo and into the residue acetonitrile (5 mL)was added. Excess of sulfur was filtered off and the filtrate was condensed in vacuo. The crude product was purified by silica gel column chromatography using chloroform as an eluent to give 9 (75mg, 90%) as a colorless oil: 31 P NMR (CDCl 3 ): 105.2 (s); FAB-MS (M-1) m/z 208. -2-oxo-1,3,2-oxathiaphospholane (14) . To a solution of 2-cyanoethoxy-2-thio-1,3,2-oxathiaphospholane (9) (75mg, 0.36mmol) in acetonitrile (1mL) SeO 2 (48mg, 0.43mmol) was added. After stirring at room temperature for 30min the reaction mixture was passed through a dry silica gel column (ca. 0.2g) to absorb SeO 2 . Then the filtrate was condensed in vacuo and the product was further used without purification. 31 P NMR (CD 3 CN):
2-Cyanoethoxy

44.6 (s) (82% purity).
2',2'-difluoro-2'-deoxycytidine-5'-O-monophosphate (1).
To a mixture of N-4,O-3'-dibenzoyl-2',2'-difluoro-2'-deoxycytidine (2) (56mg, 0.12mmol) and DBU (23mg, 24μL, 0.15mmol) in acetonitrile (2mL) a crude 2-cyanoethoxy-2-oxo-1,3,2-oxathiaphospholane (14) was added. After stirring at room temperature for 4h the mixture was condensed in vacuo and the residue was dissolved in 5 mL of 20% aqueous ammonia and left for 24 h at room temperature in a tightly closed vessel. Then the ammonia was evaporated, and the product 1 was isolated by ion-exchange chromatography (DEAE-Sephadex A-25) using triethylammonium bicarbonate buffor (TEAB, pH 7.5 from 0.0 to 0.3M) as the eluent. Then the product 1 was converted into the sodium salt using Dowex® 50 WX4 Na + and lyophilized as a white foam (29mg,0.08mmol, 67%). 
2',2'-difluoro-2'-deoxycytidine-5'-O-phosphoramidate (16)
2',2'-difluoro-2'-deoxycytidine-5'-O-monophosphate (1) (14 mg, 0.04 mmol) was dissolved in a mixture of 2 M ammonium hydroxide (100 L) and formamide (68 L) and into this solution dicyclohexylcarbodiimide (42 mg, 0.2 mmol) dissolved in tert-butyl alcohol (260 L) was added. The reaction mixture was heated at 80°C for 10 hours and then allowed to stand overnight at room temperature. The mixture was condensed in vacuo and the product was isolated using ion-exchange chromatography (DEAE-Sephadex A-25) with TEAB buffer (pH 7.5; from 0.0 to 0.3 M) as the eluent. The product 16 was obtained in 78% yield. (16) 2 ',2'-difluoro-2'-deoxycytidine-5'-O-triphosphate (15) 2',2'-difluoro-2'-deoxycytidine-5'-O-phosphoramidate (16) (29 mg, 0.085 mmol) was dissolved in anhydrous DMF (0.5mL) and 0.5 M bis-tri-n-butylammonium pyrophosphate in DMF (1.06mL) was added. After heating the homogeneous solution in a stoppered flask at 65ÛC for 13 hours the mixture was evaporated and the product was isolated using HPLC 
